# A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

Study · id `cardio:ct-nct07295418` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07295418](<https://clinicaltrials.gov/study/NCT07295418>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07295418

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 618 participants.

## Technical summary

Registry record NCT07295418. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-23 (actual); primary completion 2025-04-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 618 participants (enrolled count; ClinicalTrials.gov record NCT07295418, source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)
- Started: 2023-10-23 (actual) (ClinicalTrials.gov record NCT07295418, source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)
- Primary completion: 2025-04-22 (actual) (ClinicalTrials.gov record NCT07295418, source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)
- Completion: 2025-05-08 (actual) (ClinicalTrials.gov record NCT07295418, source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07295418, source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07295418-2025-12-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia
- Condition: Hyperlipidemias
- Intervention (Drug): SAL003 140 mg
- Intervention (Drug): Placebo
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Salubris (Chengdu) Biotechnology Co., Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: d7da155225fff9a2e43bae6d1e9e15a367a9239ef9da0e111a27f1ac7144046c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
